Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Back

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Antimicrobial Chemotherapy|November 5, 2010
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicinMohammed Lamorde, Pauline Byakika-Kibwika, Violet Okaba-Kayom, et al.
Chemotherapy Research and Practice|February 8, 2012
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan AdultsPauline Byakika-Kibwika, Mohammed Lamorde, Peter Lwabi, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite studyLucy Garvey, Mark Nelson, Ngaire Latch, et al.
AIDS Research and Treatment|March 29, 2012
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan AdultsMohammed Lamorde, Pauline Byakika-Kibwika, William S Tamale, et al.
Antiviral Therapy|July 26, 2005
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugsMarta Boffito, Edward Acosta, David Burger, et al.
Antiviral Therapy|August 20, 2003
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokineticsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
Drugs in R&D|December 18, 2020
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic ImpairmentFiona Marra, Elise J Smolders, Omar El-Sherif, et al.
AIDS (London, England)|November 7, 2015
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteersJosep Coll, José Moltó, Jaume Boix, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Francis Kalemeera, et al.
Journal of Viral Hepatitis|February 11, 2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countriesPeter Ferenci, Stefan Bourgeois, Peter Buggisch, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Antimicrobial Chemotherapy|November 5, 2010
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicinMohammed Lamorde, Pauline Byakika-Kibwika, Violet Okaba-Kayom, et al.
Chemotherapy Research and Practice|February 8, 2012
Cardiac Conduction Safety during Coadministration of Artemether-Lumefantrine and Lopinavir/Ritonavir in HIV-Infected Ugandan AdultsPauline Byakika-Kibwika, Mohammed Lamorde, Peter Lwabi, et al.
The Journal of Antimicrobial Chemotherapy|October 12, 2011
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite studyLucy Garvey, Mark Nelson, Ngaire Latch, et al.
AIDS Research and Treatment|March 29, 2012
Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan AdultsMohammed Lamorde, Pauline Byakika-Kibwika, William S Tamale, et al.
Antiviral Therapy|July 26, 2005
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugsMarta Boffito, Edward Acosta, David Burger, et al.
Antiviral Therapy|August 20, 2003
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokineticsMartina Hennessy, Susan Clarke, J Paul Spiers, et al.
Drugs in R&D|December 18, 2020
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic ImpairmentFiona Marra, Elise J Smolders, Omar El-Sherif, et al.
AIDS (London, England)|November 7, 2015
Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteersJosep Coll, José Moltó, Jaume Boix, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adultsPauline Byakika-Kibwika, Mohammed Lamorde, Francis Kalemeera, et al.
Journal of Viral Hepatitis|February 11, 2019
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countriesPeter Ferenci, Stefan Bourgeois, Peter Buggisch, et al.
Pageof 15